Fig. 3

Analgesia of DRG-AAV6-3.2iPA2 injection in female MIA rats. Analogous figures to Fig. 1 show significant analgesia after DRG delivery of AAV6-3.2iPA2 to the established MIA pain behavior in female rats. **p < 0.0.1 and ***p < 0.001 for comparisons to the treatment baseline (tBL) within the group and ^#p < 0.05, ^##p < 0.01, and ^###p < 0.001 for comparisons between the groups post-AAV injection (A–E). Repeated measures parametric two-way ANOVA for vF, Heat, and Wb followed by Tukey post hoc, and non-parametric Friedman ANOVA for pin and cold tests and Dunn’s post hoc. Right panels of A–E show tAUCs calculated using the measures 14-day post MIA and before vector injection as tBL; **p < 0.0.1 and ***p < 0.001, comparisons of tAUCs between the groups (unpaired, two-tailed Student’s t tests for vF, Heat, and Wb, and Mann–Whitney U tests for pin and cold). CPP difference scores (s) of saline-paired chamber and the GBP-paired chamber between AAV-3.2iPA2 and AAV-3.2NP, **p < 0.01 (unpaired, two-tailed Student’s t test) (F). Representative IHC montage images of GFP3.2iPA2 with Tubb3 show neuronal expression profile after AAV-3.2iPA2 injection (G). GFP-3.2iPA2 signal (green) is not detected in GFAP-positive glial cells (H, red). Scale bar, 100 μm for all images